Artivion, Inc. (AORT) · Aug 6, 2026 · Company update

Revenue beat expectations, but EBITDA guidance was cut and profitability deteriorated

Revenue beat expectations, but EBITDA guidance was cut and profitability deteriorated

Revenue clearly beat the quarter’s expectation. Revenue reached $125.8 million versus published consensus of roughly $120.0 million, a nearly 5% beat. Constant-currency growth was 9%, led by On-X at 18% and aortic stent grafts at 12%; surgical sealants remained essentially flat. (Financial Highlights; Product Revenue)

MetricQ2 2026Q2 2025Market expectation / comparison
Total revenue$125.8M$113.0M~$120.0M consensus
Constant-currency revenue growth9%——
Adjusted EBITDA$26.4M$24.8M—
Adjusted diluted EPS$0.13$0.24Around breakeven consensus
GAAP diluted EPS$(0.28)$0.03—
Free cash flow$(12.0)M$11.7M—

The underlying growth was solid, but earnings quality weakened. Adjusted EBITDA rose only 7% despite the revenue beat, while adjusted diluted EPS fell to $0.13 from $0.24. GAAP profitability swung to a $13.5 million net loss, largely reflecting higher business-development, integration, and severance costs tied to Endospan and greater amortization. (Adjusted EBITDA reconciliation; Adjusted Net Income reconciliation; Income Statement)

The bigger surprise is the guidance cut hidden behind “reaffirmation.” Revenue guidance stayed at $480 million to $496 million, but adjusted EBITDA guidance is now $92 million to $99 million, down from the $100 million to $107 million range issued after the first quarter. The company attributes roughly $8 million of 2026 expense to Endospan, so the acquisition is adding strategic reach but worsening near-term earnings expectations. (Full-Year 2026 Guidance; Q1 2026 Prior Guidance)

The balance sheet now carries materially more acquisition and execution risk. Endospan required $116.7 million of cash, funded alongside $148.9 million of new long-term debt; long-term debt rose to $363.4 million from $215.1 million at year-end. Operating cash flow was approximately breakeven for the first six months, while free cash flow was negative $18.9 million after capital spending. (Cash Flow Statement; Balance Sheet; Free Cash Flow reconciliation)

Net read: a revenue beat offset by a lower profit outlook. The quarter shows strong demand in the higher-growth stent-graft and On-X franchises and produced adjusted EPS above a roughly breakeven expectation, but the EBITDA guidance reduction, negative free cash flow, and increased leverage keep the filing from being a clean positive. The market gets better growth execution than expected, but a weaker near-term earnings and cash-conversion picture.

Original filing on SEC EDGAR

More Artivion, Inc. news

Revenue beat expectations, but EBITDA guidance was cut and profitability deteriorated | AORT Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.